Perrigo
Makes consumer self-care products through Americas and international operating segments.
Something off on this page? Send us feedback.
Profile
Sells consumer self-care products through Consumer Self-Care Americas and Consumer Self-Care International. The company combines a store-brand manufacturing heritage with international businesses, particularly in Europe and Australia.
Builds consumer self-care products on a store-brand model established from its early medicine-packaging business. Consumer Self-Care Americas serves the United States and Canada, while Consumer Self-Care International spans markets beyond them, primarily Europe and Australia.
Manufacturing developed from repackaging medicines and household goods to affordable healthcare products, and acquisitions including Omega Pharma and HRA Pharma expanded the international platform. Its latest annual-report portfolio plan included reviews of Oral Care and Infant Formula and an agreement to sell certain Dermacosmetics businesses. Ireland incorporation following the Elan acquisition defines the company's legal structure.
Company facts
Key statistics
Year to date +4.3% · Average volume (30d) 2.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | Canaccord Genuity | Reiterate | Buy | $40 | $20 | |
| Nov 6, 2025 | JP Morgan | Downgrade | Overweight | Neutral | ||
| Oct 27, 2025 | Jefferies | Reiterate | Hold | $30 | $23 | |
| Jan 14, 2025 | Argus | Downgrade | Buy | Hold | ||
| Jan 6, 2025 | Piper Sandler | Downgrade | Overweight | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.39 | $0.50 | +28.9% | $1.02B | $1.02B | +0.7% | +23.10% |
| May 6, 2026Q1 FY26 | $0.39 | $0.43 | +10.3% | $1.04B | $969.2M | −6.4% | −4.40% |
| Feb 26, 2026Q4 FY25 | $0.80 | $0.77 | −3.8% | $1.10B | $1.11B | +0.7% | −6.84% |
| Nov 5, 2025Q3 FY25 | $0.75 | $0.80 | +6.7% | $1.09B | $1.04B | −4.5% | −1.13% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.06B | $1.04B | $1.11B | $969.2M | $1.02B | |
| Gross profit | $392.3M | $362.9M | $377.1M | $362.2M | $325.5M | $313.9M | |
| Operating income | $46.9M | $45.4M | $72.6M | $84.7M | $34.2M | $23.5M | |
| Net income | −$6.4M | −$8.4M | $7.5M | −$1.42B | −$398.6M | $74.5M | |
| Diluted EPS | −$0.05 | −$0.06 | $0.05 | −$10.23 | −$2.87 | $0.53 | |
| Gross margin | 37.6% | 34.4% | 36.1% | 32.6% | 33.6% | 30.7% | |
| Operating margin | 4.5% | 4.3% | 7.0% | 7.6% | 3.5% | 2.3% |
Fiscal years (4-quarter sums)FY21 $4.14B · FY22 $4.45B · FY23 $4.66B · FY24 $4.37B · FY25 $4.25B
Revenue by product · Q4 FY25
Revenue by geography · Q2 FY26
Balance sheet, Jun 27, 2026Cash & short-term investments $399.7M · Total debt $3.29B · Total assets $7.61B · Shareholders' equity $2.52B
Dividends
Raised for 22 straight years — most recently to $0.29 from $0.276 in Mar 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 28, 2026 | Aug 28 | Sep 15 | $0.29 | |
| May 29, 2026 | May 29 | Jun 16 | $0.29 | |
| Mar 2, 2026 | Mar 2 | Mar 24 | $0.29 | |
| Nov 28, 2025 | Nov 28 | Dec 16 | $0.29 | |
| Aug 29, 2025 | Aug 29 | Sep 16 | $0.29 | |
| May 30, 2025 | May 30 | Jun 17 | $0.29 | |
| Mar 7, 2025 | Mar 7 | Mar 25 | $0.29 | raised from $0.276 |
| Nov 29, 2024 | Nov 29 | Dec 17 | $0.276 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 138.37M · Float 137.77M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 22.70M | 16.41% | 13F | Aug 7, 2026 |
| T. Rowe Price Associates, Inc. | 14.02M | 10.20% | 13G | May 7, 2026 |
| Neuberger Berman Group LLC | 10.68M | 7.72% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 9.05M | 6.54% | 13F | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 8.70M | 6.29% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 12, 2025 | Geoffrey M. Parker | director | +7,500 | $14.18 |
| Sep 8, 2025 | Abigail Lennox | officer: EVP and CSO | +1,255 | $22.41 |
| Sep 5, 2025 | Charles Atkinson | officer: EVP, General Counsel & Sec. | +1,000 | $23.20 |
Peers
- Haleon (ADR)
Global consumer-health rival across pain, oral care and digestive health
- Kenvue
Branded self-care rival in respiratory, allergy and skin health
- Procter & Gamble
Branded OTC and personal-care competitor led by Vicks and Pepto-Bismol
- Abbott
Infant-formula competitor through the Similac nutrition portfolio
- Dr. Reddy's Laboratories (ADR)
Generic-medicines manufacturer with category-specific OTC overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Perrigo | $14.44 | −0.35% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Procter & Gamble | $143.75 | +0.01% | $341.75B | 21.7 | 20.5 | 3.9 | +1.5% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Median | 22.0 | 19.4 | 3.0 | +3.0% |